, /PRNewswire/ -- , a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation by Dr. , Clinical Professor of Ophthalmology at the Health Science Center, at the taking place from at the Stockholmsmässan Convention Center in . Details for the presentation are as follows: BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: FIRST TIME 100-week TOPLINE Results from a Phase /3 Randomized Sham-Controlled Clinical Trial (RESTORE) Late-Breaking Symposium Presentation Symposium 3: Hereditary Retinal Disease & Genetics 9:17am CEST Dr.
, Clinical Professor of Ophthalmology at the Health Science Center Dr. Singer will present end-of-study data from RESTORE, a randomized controlled trial of Nanoscope's MCO optogenetic gene therapy in patients with severe vision loss related to Retinitis Pigmentosa (RP). MCO-treated subjects from RESTORE experienced clinically meaningful improvements in best-corrected visual acuity (BCVA) in a statistically significant manner.
Dr. Singer will discuss the importance and magnitude of the vision restoration observed in MCO-treated patients from RESTORE in the context of the natural history of declining vision in this patient population. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring o.